Altre lingue Aurinia Pharmaceuticals Inc.

Azioni

AUPH

CA05156V1022

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 23/04/2024			Variaz. 5gg	Var. 1 gen.
5,09 ^USD	+0,79%		+3,67%	-43,38%

20/03	ILJIN SNT ha consegnato una lettera ad Aurinia Pharmaceuticals	CI
07/03	Un insider di Aurinia Pharmaceuticals ha venduto azioni per un valore di 711.094 dollari, secondo un recente deposito SEC	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

UPDATE, NEW AURINIA PRESENTATION DETAILS AT THE 2024 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE	17/04
New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference	16/04
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024	15/04
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04
ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals	20/03
Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing	07/03
Aurinia Pharmaceuticals Insider Sold Shares Worth $323,372, According to a Recent SEC Filing	07/03
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program	29/02
Aurinia to Participate in Upcoming Investor Healthcare Conferences	27/02
Sector Update: Health Care Stocks Higher Late Afternoon	15/02
Sector Update: Health Care Stocks Higher Thursday Afternoon	15/02
Sector Update: Health Care	15/02
Aurinia Pharmaceuticals Q4 Loss Widens, Revenue Increases; Concludes Strategic Review -- Shares Slump	15/02
Aurinia: Q4 Earnings Snapshot	15/02
Aurinia Pharmaceuticals Inc. announces an Equity Buyback for $150 million worth of its shares.	15/02
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q4 Revenue $45.1M, vs. Street Est of $45.2M	15/02
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value	15/02
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02
Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Fiscal Year 2024	15/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Aurinia Pharmaceuticals Inc.

Azioni

AUPH

CA05156V1022

Altre lingue

Filtri